TDMS Study 96021-01 Pathology Tables
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
FINAL #3
Facility: Battelle Columbus Laboratory
Chemical CAS #: 35065-27-1
Lock Date: 01/16/02
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 86 98 98 98 80
Early Deaths
Natural Death 11 15 8 9 15 11
Moribund Sacrifice 18 23 17 22 18 19
Dosing Accident 1
Survivors
Terminal Sacrifice 24 16 28 20 20 21
Natural Death 1
Animals Examined Microscopically 53 54 53 53 53 51
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (53) (54) (53) (53) (53) (51)
Muscularis, Inflammation 3 (6%) 1 (2%) 2 (4%) 1 (2%)
Periesophageal Tissue, Hemorrhage 1 (2%)
Periesophageal Tissue, Inflammation 1 (2%)
Intestine Large, Colon (53) (54) (53) (53) (53) (50)
Inflammation, Chronic Active 1 (2%)
Parasite Metazoan 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Intestine Large, Rectum (53) (54) (53) (53) (53) (50)
Inflammation, Chronic Active 1 (2%)
Parasite Metazoan 1 (2%) 2 (4%) 3 (6%) 7 (13%) 5 (9%) 5 (10%)
Intestine Large, Cecum (53) (54) (53) (53) (53) (50)
Inflammation, Chronic Active 1 (2%)
Intestine Small, Duodenum (53) (54) (53) (53) (53) (51)
Parasite Metazoan 1 (2%)
Intestine Small, Jejunum (53) (54) (53) (53) (53) (50)
Peyer's Patch, Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Intestine Small, Ileum (52) (54) (53) (53) (53) (50)
Hyperplasia, Lymphoid 1 (2%)
Liver (53) (54) (53) (53) (53) (51)
Angiectasis 5 (9%) 2 (4%) 2 (4%) 1 (2%) 8 (15%) 4 (8%)
Basophilic Focus 8 (15%) 5 (9%) 16 (30%) 6 (11%) 3 (6%) 8 (16%)
Basophilic Focus, Multiple 8 (15%) 12 (22%) 9 (17%) 7 (13%) 7 (13%) 2 (4%)
Cholangiofibrosis 1 (2%)
Clear Cell Focus 3 (6%) 3 (6%) 4 (8%) 2 (4%)
Clear Cell Focus, Multiple 3 (6%) 2 (4%) 1 (2%)
Eosinophilic Focus 5 (9%) 1 (2%) 8 (15%) 7 (13%) 14 (26%) 6 (12%)
Eosinophilic Focus, Multiple 7 (13%) 1 (2%) 8 (15%) 12 (23%) 9 (17%) 12 (24%)
Fatty Change, Diffuse 3 (6%) 7 (13%) 2 (4%) 11 (21%) 21 (40%) 17 (33%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Fatty Change, Focal 4 (8%) 3 (6%) 5 (9%) 4 (8%) 1 (2%)
Hematopoietic Cell Proliferation 20 (38%) 22 (41%) 13 (25%) 18 (34%) 16 (30%) 14 (27%)
Hepatodiaphragmatic Nodule 1 (2%) 1 (2%)
Hyperplasia, Nodular 1 (2%)
Inflammation 44 (83%) 39 (72%) 44 (83%) 47 (89%) 48 (91%) 45 (88%)
Mixed Cell Focus 8 (15%) 3 (6%) 7 (13%) 6 (11%) 5 (9%) 3 (6%)
Mixed Cell Focus, Multiple 21 (40%) 16 (30%) 22 (42%) 19 (36%) 19 (36%) 12 (24%)
Necrosis 7 (13%) 7 (13%) 7 (13%) 5 (9%) 12 (23%) 10 (20%)
Pigmentation 1 (2%) 1 (2%) 2 (4%) 5 (9%) 5 (9%) 9 (18%)
Bile Duct, Cyst 3 (6%) 2 (4%) 2 (4%) 3 (6%) 5 (9%) 2 (4%)
Bile Duct, Fibrosis 2 (4%) 1 (2%) 2 (4%) 2 (4%) 2 (4%) 3 (6%)
Bile Duct, Hyperplasia 5 (9%) 3 (6%) 2 (4%) 14 (26%) 10 (19%) 17 (33%)
Centrilobular, Degeneration 2 (4%) 10 (19%) 4 (8%) 2 (4%) 2 (4%) 5 (10%)
Hepatocyte, Hypertrophy 5 (9%) 5 (9%) 24 (45%) 39 (74%) 41 (80%)
Oval Cell, Hyperplasia 1 (2%) 4 (8%)
Serosa, Fibrosis 1 (2%)
Serosa, Inflammation 2 (4%)
Mesentery (1) (1)
Fat, Inflammation, Chronic Active 1 (100%)
Oral Mucosa (21) (12) (16) (12) (16) (25)
Gingival, Hyperplasia, Squamous 21 (100%) 10 (83%) 16 (100%) 11 (92%) 16 (100%) 25 (100%)
Pancreas (53) (54) (53) (53) (53) (51)
Cyst 1 (2%)
Degeneration 1 (2%)
Inflammation, Chronic Active 2 (4%) 1 (2%) 1 (2%) 2 (4%)
Acinus, Atrophy 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Acinus, Hyperplasia 3 (6%)
Acinus, Vacuolization Cytoplasmic 1 (2%) 1 (2%) 2 (4%)
Salivary Glands (51) (52) (53) (52) (53) (51)
Ectopic Tissue 1 (2%)
Stomach, Forestomach (53) (54) (53) (53) (53) (51)
Hyperkeratosis 1 (2%) 1 (2%) 2 (4%)
Hyperplasia, Squamous 3 (6%) 4 (7%) 2 (4%) 6 (11%) 4 (8%) 4 (8%)
Inflammation 3 (6%) 3 (6%) 2 (4%)
Mineralization 1 (2%) 2 (4%) 2 (4%)
Ulcer 2 (4%) 3 (6%) 1 (2%)
Serosa, Inflammation, Chronic Active 1 (2%)
Stomach, Glandular (53) (54) (53) (53) (53) (51)
Erosion 1 (2%) 1 (2%) 2 (4%)
Inflammation 2 (4%)
Mineralization 5 (9%) 8 (15%) 8 (15%) 10 (19%) 10 (19%) 2 (4%)
Tooth (34) (13) (19) (22) (23) (35)
Degeneration 1 (3%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Peridontal Tissue, Inflammation 33 (97%) 13 (100%) 19 (100%) 21 (95%) 23 (100%) 35 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (52) (54) (53) (53) (53) (51)
Aorta, Mineralization 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Heart (52) (54) (53) (53) (53) (51)
Cardiomyopathy 22 (42%) 18 (33%) 19 (36%) 19 (36%) 23 (43%) 24 (47%)
Inflammation 2 (4%) 1 (2%) 1 (2%)
Mineralization 1 (2%) 1 (2%)
Necrosis 1 (2%)
Thrombosis 2 (4%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (53) (54) (53) (53) (53) (51)
Angiectasis 21 (40%) 23 (43%) 34 (64%) 25 (47%) 29 (55%) 21 (41%)
Atrophy 1 (2%) 2 (4%)
Degeneration, Cystic 9 (17%) 12 (22%) 15 (28%) 13 (25%) 12 (23%) 13 (25%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%) 3 (6%)
Hyperplasia 18 (34%) 24 (44%) 27 (51%) 27 (51%) 28 (53%) 11 (22%)
Hypertrophy 48 (91%) 35 (65%) 45 (85%) 35 (66%) 42 (79%) 41 (80%)
Inflammation 1 (2%) 1 (2%)
Mineralization 2 (4%) 1 (2%)
Necrosis 1 (2%) 2 (4%) 1 (2%) 2 (4%) 3 (6%) 3 (6%)
Vacuolization Cytoplasmic 10 (19%) 8 (15%) 14 (26%) 16 (30%) 12 (23%) 14 (27%)
Adrenal Medulla (53) (54) (53) (53) (53) (51)
Angiectasis 1 (2%) 1 (2%)
Hyperplasia 18 (34%) 14 (26%) 19 (36%) 14 (26%) 20 (38%) 12 (24%)
Islets, Pancreatic (53) (54) (53) (53) (53) (51)
Hyperplasia 1 (2%) 1 (2%) 1 (2%)
Parathyroid Gland (49) (46) (50) (47) (46) (48)
Angiectasis 1 (2%)
Cyst 1 (2%)
Fibrosis 1 (2%)
Hyperplasia 2 (4%) 1 (2%) 1 (2%)
Pituitary Gland (53) (54) (53) (53) (53) (50)
Angiectasis 15 (28%) 16 (30%) 20 (38%) 26 (49%) 28 (53%) 14 (28%)
Atypia Cellular 1 (2%)
Cyst 1 (2%) 1 (2%)
Cytoplasmic Alteration 2 (4%) 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Vacuolization Cytoplasmic 1 (2%)
Pars Distalis, Hyperplasia 23 (43%) 18 (33%) 22 (42%) 16 (30%) 23 (43%) 25 (50%)
Thyroid Gland (51) (52) (53) (53) (53) (51)
Angiectasis 1 (2%) 1 (2%)
C-Cell, Hyperplasia 19 (37%) 17 (33%) 23 (43%) 17 (32%) 19 (36%) 16 (31%)
Follicular Cell, Hyperplasia 1 (2%) 2 (4%) 2 (4%)
Follicular Cell, Hypertrophy 5 (10%) 9 (17%) 9 (17%) 12 (23%) 10 (19%) 17 (33%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (53) (51) (52) (53) (51) (50)
Atrophy 1 (2%)
Inflammation 52 (98%) 45 (88%) 41 (79%) 48 (91%) 48 (94%) 46 (92%)
Inflammation, Chronic Active 1 (2%)
Duct, Cyst 49 (92%) 40 (78%) 36 (69%) 43 (81%) 45 (88%) 41 (82%)
Ovary (53) (53) (53) (53) (53) (50)
Atrophy 47 (89%) 43 (81%) 42 (79%) 38 (72%) 44 (83%) 39 (78%)
Cyst 14 (26%) 7 (13%) 17 (32%) 17 (32%) 16 (30%) 17 (34%)
Inflammation, Chronic Active 2 (4%) 1 (2%) 5 (9%) 7 (14%)
Necrosis 1 (2%)
Interstitial Cell, Hyperplasia 1 (2%) 1 (2%)
Oviduct (50) (38) (44) (35) (39) (45)
Cyst 1 (3%) 2 (5%) 1 (3%) 1 (3%)
Dilatation 1 (2%) 1 (2%)
Inflammation, Chronic Active 1 (2%) 2 (5%) 1 (3%) 5 (13%) 7 (16%)
Uterus (53) (54) (53) (53) (53) (50)
Adenomyosis 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Angiectasis 1 (2%) 1 (2%)
Congestion 1 (2%)
Cyst 1 (2%) 1 (2%)
Hemorrhage 2 (4%)
Inflammation, Chronic Active 2 (4%) 1 (2%) 5 (9%) 4 (8%) 2 (4%) 8 (16%)
Inflammation, Suppurative 5 (9%) 6 (11%) 6 (11%) 2 (4%) 16 (30%) 8 (16%)
Metaplasia, Squamous 23 (43%) 29 (54%) 27 (51%) 17 (32%) 27 (51%) 32 (64%)
Thrombosis 1 (2%) 2 (4%)
Ulcer 1 (2%)
Cervix, Hyperplasia, Stromal 1 (2%) 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Cervix, Inflammation, Suppurative 1 (2%)
Endometrium, Hyperplasia, Cystic 37 (70%) 29 (54%) 32 (60%) 28 (53%) 25 (47%) 21 (42%)
Endometrium, Hyperplasia, Stromal 1 (2%)
Vagina (1) (3) (2) (1) (1) (3)
Inflammation 1 (50%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (54) (53) (53) (53) (51)
Hyperplasia 34 (64%) 41 (76%) 40 (75%) 38 (72%) 42 (79%) 46 (90%)
Lymph Node (3) (3) (3) (2) (5) (6)
Hemorrhage 1 (33%)
Hyperplasia, Lymphoid 1 (33%)
Hyperplasia, Plasma Cell 1 (33%) 1 (33%)
Iliac, Ectasia 1 (20%)
Iliac, Hyperplasia, Plasma Cell 1 (20%)
Lumbar, Ectasia 1 (33%) 2 (67%) 2 (33%)
Lumbar, Hemorrhage 1 (33%) 1 (17%)
Lumbar, Hyperplasia, Histiocytic 1 (20%)
Lumbar, Hyperplasia, Plasma Cell 1 (20%) 2 (33%)
Mediastinal, Congestion 3 (100%)
Mediastinal, Ectasia 2 (33%)
Mediastinal, Hyperplasia, Histiocytic 1 (33%)
Mediastinal, Hyperplasia, Lymphoid 1 (33%) 1 (33%)
Mediastinal, Hyperplasia, Plasma Cell 1 (33%) 1 (33%)
Renal, Ectasia 2 (33%)
Renal, Hyperplasia, Plasma Cell 1 (17%)
Renal, Inflammation, Chronic Active 1 (50%)
Lymph Node, Mandibular (51) (52) (53) (51) (53) (51)
Congestion 1 (2%)
Ectasia 1 (2%) 1 (2%) 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 1 (2%) 2 (4%) 1 (2%) 3 (6%) 1 (2%)
Hyperplasia, Plasma Cell 37 (73%) 36 (69%) 30 (57%) 33 (65%) 37 (70%) 38 (75%)
Inflammation 1 (2%)
Lymph Node, Mesenteric (52) (54) (53) (53) (53) (51)
Ectasia 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia, Plasma Cell 1 (2%)
Inflammation, Chronic Active 1 (2%)
Spleen (53) (54) (53) (53) (53) (51)
Hematopoietic Cell Proliferation 46 (87%) 48 (89%) 52 (98%) 48 (91%) 46 (87%) 47 (92%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hemorrhage 1 (2%)
Infarct 1 (2%)
Necrosis 1 (2%) 1 (2%) 1 (2%)
Pigmentation 47 (89%) 42 (78%) 47 (89%) 49 (92%) 49 (92%) 46 (90%)
Lymphoid Follicle, Atrophy 1 (2%) 6 (11%) 2 (4%) 3 (6%) 3 (6%) 3 (6%)
Red Pulp, Atrophy 2 (4%)
Thymus (48) (53) (52) (53) (53) (47)
Atrophy 38 (79%) 38 (72%) 37 (71%) 35 (66%) 41 (77%) 30 (64%)
Cyst 1 (2%) 1 (2%)
Hemorrhage 3 (6%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (54) (53) (53) (53) (51)
Cyst 2 (4%) 1 (2%) 2 (4%) 1 (2%) 3 (6%)
Hyperplasia 22 (42%) 23 (43%) 32 (60%) 27 (51%) 32 (60%) 22 (43%)
Inflammation, Chronic Active 1 (2%)
Inflammation, Granulomatous 2 (4%) 2 (4%) 3 (6%) 1 (2%)
Skin (53) (54) (53) (53) (53) (51)
Cyst 1 (2%)
Cyst Epithelial Inclusion 1 (2%) 1 (2%)
Inflammation 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (54) (53) (53) (53) (51)
Hemorrhage 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Hydrocephalus 2 (4%) 1 (2%)
Hyperplasia, Histiocytic 1 (2%)
Mineralization 1 (2%)
Necrosis 1 (2%) 1 (2%)
Vacuolization Cytoplasmic 1 (2%)
Glial Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (52) (54) (53) (53) (53) (51)
Congestion 1 (2%)
Hemorrhage 1 (2%) 1 (2%)
Infiltration Cellular, Histiocyte 45 (87%) 40 (74%) 40 (75%) 40 (75%) 27 (51%) 28 (55%)
Inflammation 6 (12%) 7 (13%) 2 (4%) 6 (11%) 7 (13%) 9 (18%)
Metaplasia, Squamous 1 (2%) 1 (2%) 1 (2%)
Mineralization 1 (2%) 1 (2%)
Alveolar Epithelium, Hyperplasia 20 (38%) 21 (39%) 16 (30%) 11 (21%) 9 (17%) 6 (12%)
Mediastinum, Hemorrhage 1 (2%)
Serosa, Inflammation, Chronic Active 1 (2%)
Nose (53) (54) (53) (53) (53) (51)
Cyst 1 (2%)
Inflammation 1 (2%) 6 (11%) 3 (6%) 6 (11%) 6 (11%) 3 (6%)
Goblet Cell, Hyperplasia 2 (4%) 1 (2%) 2 (4%)
Nasolacrimal Duct, Inflammation 2 (4%) 2 (4%)
Respiratory Epithelium, Hyperplasia 2 (4%) 1 (2%)
Respiratory Epithelium, Mineralization 1 (2%)
Septum, Inflammation 4 (8%) 3 (6%) 5 (9%) 3 (6%) 7 (13%) 6 (12%)
Squamous Epithelium, Hyperplasia 1 (2%)
Turbinate, Inflammation 8 (15%) 3 (6%) 5 (9%) 9 (17%) 10 (19%) 10 (20%)
Trachea (52) (54) (53) (53) (53) (51)
Inflammation 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (53) (54) (53) (53) (52) (51)
Degeneration 1 (2%)
Anterior Chamber, Exudate 1 (2%)
Lens, Degeneration 1 (2%)
Retina, Atrophy 2 (4%) 1 (2%) 1 (2%)
Harderian Gland (53) (54) (53) (53) (53) (49)
Atrophy 1 (2%)
Inflammation 20 (38%) 9 (17%) 13 (25%) 16 (30%) 16 (30%) 16 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (54) (53) (53) (53) (51)
Accumulation, Hyaline Droplet 3 (6%) 1 (2%) 1 (2%)
Calculus Micro Observation Only 3 (6%) 5 (9%) 4 (8%) 7 (13%) 5 (9%) 1 (2%)
Casts Protein 3 (6%) 2 (4%) 2 (4%) 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Cyst 1 (2%) 1 (2%)
Degeneration 1 (2%)
Hydronephrosis 1 (2%) 1 (2%)
Infarct 1 (2%) 1 (2%) 2 (4%)
Inflammation, Chronic Active 2 (4%) 3 (6%) 1 (2%)
Inflammation, Suppurative 1 (2%) 2 (4%) 3 (6%) 2 (4%) 2 (4%) 3 (6%)
Mineralization 40 (75%) 42 (78%) 41 (77%) 39 (74%) 40 (75%) 41 (80%)
Necrosis 1 (2%)
Nephropathy 34 (64%) 23 (43%) 24 (45%) 33 (62%) 28 (53%) 34 (67%)
Pelvis, Dilatation 2 (4%)
Pelvis, Inflammation 1 (2%) 4 (7%) 2 (4%) 4 (8%) 5 (9%) 4 (8%)
Renal Tubule, Degeneration 1 (2%) 1 (2%)
Renal Tubule, Hyperplasia 1 (2%)
Transitional Epithelium, Hyperplasia 1 (2%) 5 (9%) 2 (4%) 4 (8%) 6 (11%) 4 (8%)
Ureter (1)
Cyst 1 (100%)
Urinary Bladder (53) (53) (53) (53) (53) (50)
Calculus Micro Observation Only 1 (2%)
Inflammation 8 (15%) 11 (21%) 6 (11%) 8 (15%) 13 (25%) 9 (18%)
Transitional Epithelium, Hyperplasia 3 (6%) 2 (4%) 3 (6%) 2 (4%) 3 (6%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50
Early Deaths
Natural Death 14
Moribund Sacrifice 16
Survivors
Terminal Sacrifice 20
Animals Examined Microscopically 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (49)
Muscularis, Inflammation 3 (6%)
Intestine Large, Rectum (50)
Parasite Metazoan 3 (6%)
Intestine Large, Cecum (48)
Inflammation 1 (2%)
Ulcer 1 (2%)
Liver (50)
Angiectasis 8 (16%)
Basophilic Focus 8 (16%)
Basophilic Focus, Multiple 2 (4%)
Clear Cell Focus 1 (2%)
Degeneration, Cystic 1 (2%)
Eosinophilic Focus 4 (8%)
Eosinophilic Focus, Multiple 10 (20%)
Fatty Change, Diffuse 15 (30%)
Fatty Change, Focal 6 (12%)
Hematopoietic Cell Proliferation 17 (34%)
Hepatodiaphragmatic Nodule 2 (4%)
Hyperplasia, Histiocytic 1 (2%)
Hyperplasia, Nodular 1 (2%)
Inflammation 44 (88%)
Mixed Cell Focus 7 (14%)
Mixed Cell Focus, Multiple 13 (26%)
Necrosis 9 (18%)
Pigmentation 3 (6%)
Bile Duct, Cyst 3 (6%)
Bile Duct, Fibrosis 5 (10%)
Bile Duct, Hyperplasia 12 (24%)
Centrilobular, Degeneration 5 (10%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Hepatocyte, Hypertrophy 32 (64%)
Oval Cell, Hyperplasia 2 (4%)
Oral Mucosa (15)
Gingival, Hyperplasia, Squamous 15 (100%)
Pancreas (50)
Inflammation, Chronic Active 2 (4%)
Acinus, Atrophy 3 (6%)
Acinus, Hyperplasia 2 (4%)
Acinus, Vacuolization Cytoplasmic 1 (2%)
Salivary Glands (48)
Inflammation, Chronic Active 1 (2%)
Stomach, Forestomach (50)
Hyperkeratosis 2 (4%)
Hyperplasia, Squamous 5 (10%)
Inflammation 4 (8%)
Mineralization 3 (6%)
Stomach, Glandular (50)
Inflammation 1 (2%)
Mineralization 3 (6%)
Ulcer 1 (2%)
Serosa, Inflammation 1 (2%)
Tooth (27)
Peridontal Tissue, Inflammation 27 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50)
Cardiomyopathy 15 (30%)
Epicardium, Inflammation 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50)
Angiectasis 20 (40%)
Degeneration, Cystic 7 (14%)
Hematopoietic Cell Proliferation 2 (4%)
Hyperplasia 18 (36%)
Hypertrophy 35 (70%)
Necrosis 1 (2%)
Vacuolization Cytoplasmic 12 (24%)
Adrenal Medulla (50)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Angiectasis 1 (2%)
Hyperplasia 19 (38%)
Parathyroid Gland (45)
Hyperplasia 1 (2%)
Pituitary Gland (50)
Angiectasis 24 (48%)
Pars Distalis, Hyperplasia 18 (36%)
Rathke's Cleft, Pars Nervosa, Cyst 1 (2%)
Thyroid Gland (49)
C-Cell, Hyperplasia 13 (27%)
Follicular Cell, Hypertrophy 12 (24%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (48)
Inflammation 44 (92%)
Duct, Cyst 41 (85%)
Ovary (49)
Atrophy 41 (84%)
Cyst 16 (33%)
Oviduct (46)
Dilatation 1 (2%)
Inflammation, Chronic Active 2 (4%)
Uterus (49)
Cyst 1 (2%)
Inflammation, Chronic Active 1 (2%)
Inflammation, Suppurative 9 (18%)
Metaplasia, Squamous 24 (49%)
Cervix, Cyst 1 (2%)
Cervix, Hyperplasia, Stromal 2 (4%)
Endometrium, Hyperplasia, Cystic 23 (47%)
Vagina (1)
Inflammation, Chronic Active 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Bone Marrow (50)
Hyperplasia 40 (80%)
Lymph Node (1)
Mediastinal, Hemorrhage 1 (100%)
Lymph Node, Mandibular (48)
Ectasia 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Hyperplasia, Plasma Cell 37 (77%)
Inflammation 1 (2%)
Spleen (50)
Accessory Spleen 1 (2%)
Congestion 1 (2%)
Hematopoietic Cell Proliferation 44 (88%)
Hemorrhage 1 (2%)
Pigmentation 50 (100%)
Lymphoid Follicle, Atrophy 4 (8%)
Thymus (49)
Atrophy 29 (59%)
Hemorrhage 1 (2%)
Inflammation 1 (2%)
Necrosis, Lymphoid 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50)
Cyst 3 (6%)
Cyst, Multiple 1 (2%)
Hyperplasia 27 (54%)
Inflammation, Granulomatous 2 (4%)
Skin (50)
Ulcer 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 10/09/03
Route: GAVAGE Time: 09:34:31
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50)
Hemorrhage 1 (2%)
Infiltration Cellular, Histiocyte 37 (74%)
Inflammation 9 (18%)
Alveolar Epithelium, Hyperplasia 4 (8%)
Nose (50)
Inflammation 2 (4%)
Septum, Inflammation 4 (8%)
Turbinate, Inflammation 5 (10%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50)
Retina, Atrophy 2 (4%)
Harderian Gland (50)
Inflammation 15 (30%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50)
Casts Protein 4 (8%)
Cyst 1 (2%)
Fibrosis 1 (2%)
Inflammation, Chronic Active 3 (6%)
Inflammation, Suppurative 2 (4%)
Mineralization 38 (76%)
Nephropathy 22 (44%)
Pelvis, Inflammation 3 (6%)
Transitional Epithelium, Hyperplasia 4 (8%)
Urinary Bladder (49)
Inflammation 10 (20%)
Transitional Epithelium, Hyperplasia 3 (6%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------